Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology Forecast to 2030
HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help stop tumor growth.
A number of classes of antiestrogenic agents available for patients with early, advanced, or metastatic breast cancer includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader.
The DelveInsight Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer epidemiology report gives a thorough understanding of the Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in the US, Europe, and Japan. The report covers the detailed information of the Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer epidemiology scenario in seven major countries (US, EU5, and Japan).
Request for Sample Pages:
Key Highlights Of The Report
-
The total incident population of breast cancer in the 7MM is expected to rise to 698,212 in 2030, during the study period [2017–2030].
-
Among the 7MM, the US accounts for the 80.51% USD of the overall market size of ER-positive/HER2-negative Breast Cancer in 2017.
-
In Japan, a higher number of cases were observed for postmenopausal Breast cancer, i.e., 71,280 cases post-menopause category, while only 17,820 patients were observed for premenopause in 2017.
-
The most incident cases of ER+/HER– breast cancer were recorded in the United States.
-
The lowest incident population of ER+/HER– breast cancer was recorded in Japan.
-
Among the EU5 countries, Germany accounts for the highest market size for ER-positive/HER2-negative Breast Cancer followed by France, Italy, the UK, and Spain.
Hormone receptors are proteins that receive hormone signals and initiate the cancer cells to grow. If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Breast cancer cells may have one, both, or none of these receptors.
-
Delveinsight’s Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries.
-
The Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM.
-
The Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030.
-
It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Scope of the Report
-
The report provides insight into the historical and forecasted patient pool of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
-
The report assesses the disease risk and burden and highlights the unmet needs of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer.
-
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
-
The Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer report provides a detailed overview explaining Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
-
The Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).
-
The report provides the segmentation of the Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer epidemiology.
Key Benefit of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology Report
The Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology report will allow the user to –
-
Develop business strategies by understanding the trends shaping and driving the global Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer market
-
Quantify patient populations in the global Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer market to improve product design, pricing, and launch plans
-
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer therapeutics in each of the markets covered
-
Understand the magnitude of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer population by its epidemiology
-
The Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Request for Sample Pages:
Table of Contents
-
Key Insights
-
Executive Summary of Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer
-
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Disease Background and Overview
-
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Patient Journey
-
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology and Patient Population
-
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
-
KOL Views on Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer
-
Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Unmet Needs
-
Appendix
-
DelveInsight Capabilities
-
Disclaimer
*The table of contents is not exhaustive; will be provided in the final report
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Related Reports
DelveInsight’s ‘Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer-Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the HR-positive/ HER2-negative breast cancer, historical and forecasted epidemiology as well as the HR-positive/ HER2-negative breast cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Epidemiology Forecast to 2030){kind=link}